Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
Trial details
- Registry ID
- NCT04412863
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as PEG-IFNα; pegylated interferon alpha-2a
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionNCT04412863 | VIR | Phase 2 | Completed | 2024-03-25Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |